



Atty. Dkt. No.	M#	Client Ref.
	0280639	1994-30-0141C3

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: REFF et al.	
Appln. No.: 09/888,639	
Filing Date: June 26, 2001	
Examiner: P. Gambel	Group Art Unit: 1644

Date: April 14, 2003 Page 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
* <i>PC</i>	AR	5,474,771	12/1995	Lederman			
	BR	5,876,718	03/1999	Noelle et al.			
	CR	5,902,585	05/1999	Noelle et al.			
	DR	5,597,563	01/1997	Beschorner			
	ER	6,056,956	05/2000	Cobbold et al.			
	FR	6,403,091	06/2001	Lederman et al.			

RECEIVED
APR 17 2003
TECH CENTER 1600/2901

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
						Enclosed	No
*		GR	WO94/04570	03/1994	PCT		
*		HR	WO93/09812	05/1993	PCT		
*		IR	WO93/08207	04/1993	PCT		
*		JR	EP0555880	08/1993	EPO		
*		KR	EP0585943	03/1994	EPO		
		LR					
		MR					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)


*	NR	MARKEES et al., "Tolerance to islet xenografts induced by dual manipulation of antigen presentation and co-stimulation," <i>Transplant Proc.</i> , 28:814-815, (1996).			
*	OR	GERRITSE et al., "CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.," <i>Proc. Natl. Acad. Sci. USA</i> , 93:2499-2504, (1996).			
*	PR	TISCH et al., "Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity?," <i>Proc. Natl. Acad. Sci. USA</i> , 91:437-438, (1994).			
*	QR	SHARKEY et al., "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," <i>Cancer Res.</i> , 55(23 Suppl):5935s-5945s, (1995).			
*	RR	LARSEN et al., "CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway," <i>Transplantation</i> , 61:4-9, (1996).			
*	SR	ROSSINI et al., "Induction of immunological tolerance to islet allografts," <i>Cell Transplantation</i> , 5:49-52, (1996).			
*	TR	BHATIA et al., "9th Intl. Congress of Immunology," San Francisco, California, USA, p. 311, (1995).			
*	UR	DURIE et al., "Allogeneic Tolerance Induced by Treatment with an Antibody to the Ligand for CD40," <i>FASEB Journal</i> , 8 (4):a477, (1997).			
*	VR	MONACO, "," <i>Immunomethods</i> , 2:159-170, (1993).			
* <i>PC</i>	WR	PULITO et al., "Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A," <i>J. Immunol.</i> , 150:2840-2850 (1996).			

Gambel 6/30/03

* Q	XR	WEE et al., "Anti-CD40 mAb therapy significantly delays the alloantibody response in a cynomolgus renal transplant model. Transplantation," <i>Transplantation</i> , 58:261-264, (1994).				
* APR 14 2003	YR	PAUL et al., "Fundamental Immunology, Raven Press, p. 242, (1993).				
* PATENT & TRADEMARK OFFICE	2R	MARSHALL et al., "The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39," <i>J. Clin. Immunol.</i> , 3(3):165-173, (1993).				
		CLARK AND LEDBETTER, "How B and T Cells Talk to Each Other," <i>Nature</i> , 367:425-428, (1994).				
*	BBR	ARUFFO et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked Hyper-IgM Syndrome," <i>Cell</i> , 72:291-300, (1993).				
*	CCR	KORTHAUER et al., "Defective expression of T cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM," <i>Nature</i> , 361:539-541 (1993).				
*	DDR	DISANTO et al., "CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM," <i>Science</i> , 259:990-993 (1993).				
*	EER	ALLEN et al., "CD40 ligand gene defects responsible for X-linked Hyper-IgM syndrome," <i>Science</i> , 259:990-993, (1993).				
*	FFR	RANHEIM et al., "Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal," <i>J. Exp. Med.</i> , 177:925-935, (1993).				
*	GGR	FOY et al., "In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39," <i>J. Exp. Med.</i> , 178:1567-1575, (1993).				
*	HHR	LIN et al., "Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion," <i>J. Exp. Med.</i> , 178:1801-1806 (1993).				
*	IIR	HARRIS, "Therapeutic antibodies - the coming of age," <i>TIBTECH</i> , 11:42-44, (1993).				
*	JJR	NOELLE et al., "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells," <i>Proc. Natl. Acad. Sci. USA</i> , 89:6550-6554, (1992).				
*	KKR	NOELLE et al., "CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation," <i>Immunol. Today</i> , 13:431-433, (1992).				
*	LLR	HOLLENBAUGH et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," <i>EMBO J.</i> , 11:4313-4321, (1992).				
*	MMR	ARMITAGE et al., "Molecular and biological characterization of a murine ligand for CD40," <i>Nature</i> , 357:80-82, (1992).				
*	NNR	LANE et al., "Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes," <i>Eur. J. Immunol.</i> , 22:2573-2578, (1992).				
*	OOR	LEDERMAN et al., "Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help)," <i>J. Exp. Med.</i> , 175:1091-1101, (1992).				
*	PPR	SPRIGGS et al., "Recombinant Human CD40 ligand stimulates B cell proliferation and Immunoglobulin E secretion," <i>J. Exp. Med.</i> , p176:1543-1550, (1992).				
*	QQR	LEDERMAN et al., "Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles," <i>J. Immunol.</i> , 149(12):3817-3826, (1992).				
*	RRR	FANSLOW et al., "Soluble forms of CD40 inhibit biological responses of human B cells," <i>J. Immunol.</i> , 149:655-660, (1992).				
*	SSR	EYNON et al., "Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens," <i>J. Exp. Med.</i> , 175:131-138, (1992).				
*	TTR	LINSLEY et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> , 257:792-795, (1992).				
* K	UUR	LENSCHOW et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig," <i>Science</i> , 257:789-790, (1992).				

RECEIVED
APR 17 2003
TECH CENTER 1600/26000

Gamba 6/30/03



		TURKA et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo," <i>Proc. Natl. Acad. Sci. USA</i> , 89:11102-11105, (1992).				
		WALDMANN, "Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection," <i>Annu. Rev. Immunol.</i> , 10:675-704, (1992).				
*		XXR NOELLE et al., "T helper Cells," <i>Curr. Opin. Immunol.</i> , 4:333-337, (1992).				
*		YYR YELLIN et al., "A human CD4- T cell leukemia subclone with contact-dependent helper function," <i>J. Immunol.</i> , 147:3389-3395, (1991).				
*		ZZR WALDMANN, "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> , 52:1657-1662, (1991).				
*		AAAR BARTLETT et al., "Cognate interactions between helper T cells and B cells. IV. Requirements for the expression of effector phase activity by helper T cells," <i>J. Immunol.</i> , 145(12):3956-3962, (1990).				
*		BBBR HODGKIN et al., "Separation of events mediating B cell proliferation and Ig production by using T cell membranes and lymphokines," <i>J. Immunol.</i> , 145(7):2025-2034, (1990).				
*		CCCR ARUFFO et al., "CD44 is the principal cell surface receptor for hyaluronate," <i>Cell</i> , 61:1303-1313, (1990).				
*		DDDR STAMENKOVIC et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> , 8(5):1403-1410, (1989).				
*		EEER PAULIE et al., "The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction," <i>J. Immunol.</i> , 142:590-595, (1989).				
*		FFFR SHARABI et al., "Mixed Chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen," <i>J. Exp. Med.</i> , 169:493-502, (1989).				
*		GGGR DILLMAN, "Monoclonal antibodies for treating Cancer," <i>Ann. Intern. Med.</i> , 111(7):592-603, (1989).				
*		HHHR WALDMANN, "Manipulation of T cell responses with monoclonal antibodies," <i>Annu. Rev. Immunol.</i> , 7:407-444, (1989).				
*		IIIR COBBOLD et al., "Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance," <i>Nature</i> , 323:164-166, (1986).				
		JJJR NORMAN et al., "Treatment of Cat Allergy With T-cell Reactive Peptides," <i>American Journal of Respiratory and Critical Care Medicine</i> , 154:1623-1628, (1996).				
		KKKR FUKAURA et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor- β 1-Secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients," <i>Journal of Clinical Investigation</i> , 98:70-77, (1996).				
		LLLR WEINER et al., "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annual Review of Immunology</i> , 12:809-837, (1994).				
		MMMR MORELAND et al., "Use of a Chimeric Monoclonal Anti-CD4 Antibody in Patients With Refractory Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> , 36:307-318, (1993).				
		NNNR VARNEY et al., "Influence of Grass Pollen Immunotherapy on Cellular Infiltration and Cytokine mRNA Expression During Allergen-Induced Late-Phase Cutaneous Responses," <i>Journal of Clinical Investigation</i> , 92:644-651, (1993).				
		OOOR TRENTHAM et al., "Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis," <i>Science</i> , 261:1727-1730, (1993).				

RECEIVED
APR 17 2003
TECH CENTER 1600/2900

Examiner Gammal 6/30/03

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.

Asterisk (*) indicates that the references were cited by or submitted to the Office in parent application no. 09/355,522, filed October 22, 1999, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these references are not attached. 37 C.F.R. § 1.98(d).